TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M

TG THERAPEUTICS, INC.

Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.
2026 target total global revenue $875-900M; U.S. BRIUMVI net product rev $825-850M.
2026 operating expense target ~$350M (excl. SBC) + ~$100M for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up.
Pipeline milestones: ENHANCE IV BRIUMVI trial data mid-2026; subcutaneous BRIUMVI topline year-end 2026/1Q 2027; azer-cel Phase 1 data in Progressive MS H2 2026.
Plans to commence registration-directed trial for BRIUMVI outside MS and additional exploratory studies in autoimmune disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.